Investors previously responded coolly to CagriSema after initial overall phase 3 trial results showed a 22.7% weight loss, falling below Novo Nordisk's targeted 25% expectation

From the articleNovo's CagriSema helped women lose 25% of weight on average, analysis shows | ReutersAlso in Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis